

Peter C M Van De Kerkhof

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7221253/publications.pdf>

Version: 2024-02-01

215
papers

7,251
citations

57752

44
h-index

82542

72
g-index

222
all docs

222
docs citations

222
times ranked

6042
citing authors

#	ARTICLE	IF	CITATIONS
1	Two-year follow-up of a dose reduction strategy trial of biologics adalimumab, etanercept, and ustekinumab in psoriasis patients in daily practice. <i>Journal of Dermatological Treatment</i> , 2022, 33, 1591-1597.	2.2	4
2	Exploring patient journeys through acne healthcare: a patient perspective. <i>Journal of Dermatological Treatment</i> , 2022, 33, 2209-2216.	2.2	4
3	Predictors of surgical treatment burden, outcomes, and overall survival in older adults with basal cell carcinoma: Results from the prospective, multicenter BATOA cohort. <i>Journal of the American Academy of Dermatology</i> , 2022, 86, 1010-1019.	1.2	9
4	Optimizing shared decision making in older adults with basal cell carcinoma: experiences from a specialized outpatient clinic. <i>British Journal of Dermatology</i> , 2022, 186, 589-591.	1.5	2
5	Evolution of Patient Perceptions of Psoriatic Disease: Results from the Understanding Psoriatic Disease Leveraging Insights for Treatment (UPLIFT) Survey. <i>Dermatology and Therapy</i> , 2022, 12, 61-78.	3.0	18
6	Foreword. <i>American Journal of Clinical Dermatology</i> , 2022, 23, 3-4.	6.7	0
7	Serum drug levels and anti-drug antibodies in the context of dose tapering by interval prolongation of adalimumab, etanercept and ustekinumab in psoriasis patients: results of the CONDOR trial. <i>Journal of Dermatological Treatment</i> , 2022, 33, 2680-2684.	2.2	4
8	Dermatology in a changing world. <i>Journal of Dermatological Treatment</i> , 2022, 33, 605-605.	2.2	1
9	From Empirical to Pathogenesis-Based Treatments for Psoriasis. <i>Journal of Investigative Dermatology</i> , 2022, 142, 1778-1785.	0.7	28
10	Frailty screening in dermatology practice: a modified Delphi study and a systematic review of the literature. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2021, 35, 95-104.	2.4	12
11	Long-term safety of certolizumab pegol in plaque psoriasis: pooled analysis over 3 years from three phase III, randomized, placebo-controlled studies. <i>British Journal of Dermatology</i> , 2021, 184, 640-651.	1.5	16
12	Quality of life, treatment goals, preferences and satisfaction in older adults with psoriasis: a patient survey comparing age groups. <i>British Journal of Dermatology</i> , 2021, 184, 759-762.	1.5	11
13	Vasculature in the Margin of the Psoriatic Lesion. <i>Journal of Psoriasis and Psoriatic Arthritis</i> , 2021, 6, 106-112.	0.7	0
14	Pioneers in Dermatology and Venereology: An Interview with Professor Peter van de Kerkhof. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2021, 35, 1041-1042.	2.4	0
15	Structure, quality and accessibility of the Dutch acne healthcare; a care providers' perspective. <i>Journal of Dermatological Treatment</i> , 2021, 32, 269-276.	2.2	2
16	Efficacy of dimethyl fumarate treatment for moderate-to-severe plaque psoriasis: presentation extracts from the 29th EADV virtual congress, 29-31 October 2020. <i>Expert Review of Clinical Immunology</i> , 2021, 17, 1-11.	3.0	7
17	Future perspectives on care for patients with psoriasis. What did we learn during the COVID-19. <i>Journal of Dermatological Treatment</i> , 2021, 32, 477-477.	2.2	1
18	Reallocations in acne healthcare: exploring the possible roles and added value of non-physicians by a mixed-methods study design. <i>BMC Health Services Research</i> , 2021, 21, 746.	2.2	0

#	ARTICLE	IF	CITATIONS
19	The risk of malignancy in patients with secukinumab-treated psoriasis, psoriatic arthritis and ankylosing spondylitis. British Journal of Dermatology, 2021, 185, 879-879.	1.5	1
20	Evaluation of Watchful Waiting and Tumor Behavior in Patients With Basal Cell Carcinoma. JAMA Dermatology, 2021, 157, 1174.	4.1	16
21	Treatment goals in psoriasis from a patient perspective: a qualitative study. Journal of Dermatological Treatment, 2020, 31, 13-17.	2.2	18
22	Recategorization of psoriasis severity: Delphi consensus from the International Psoriasis Council. Journal of the American Academy of Dermatology, 2020, 82, 117-122.	1.2	120
23	Quality of life outcomes in adults with moderate-to-severe plaque psoriasis treated with dimethylfumarate (DMF): a post hoc analysis of the BRIDGE study. Journal of the European Academy of Dermatology and Venereology, 2020, 34, 119-126.	2.4	15
24	Our ambition in a changing landscape of psoriasis treatments. Journal of Dermatological Treatment, 2020, 31, 105-107.	2.2	0
25	Association Between Quality of Life and Improvement in Psoriasis Severity and Extent in Pediatric Patients. JAMA Dermatology, 2020, 156, 72.	4.1	14
26	Effectiveness and Safety of Systemic Therapy for Psoriasis in Older Adults. JAMA Dermatology, 2020, 156, 1229.	4.1	16
27	Dermatology before, during and after COVID 19. Journal of Dermatological Treatment, 2020, 31, 435-435.	2.2	0
28	Phototherapy in the perspective of the chronicity of psoriasis. Journal of the European Academy of Dermatology and Venereology, 2020, 34, 926-931.	2.4	8
29	Translational Research and Drug Development in Psoriasis by Collaborative Efforts of Academia and Industry. Journal of Investigative Dermatology, 2020, 140, 524-526.	0.7	1
30	The Validated Investigator Global Assessment for Atopic Dermatitis (vIGA-AD): The development and reliability testing of a novel clinical outcome measurement instrument for the severity of atopic dermatitis. Journal of the American Academy of Dermatology, 2020, 83, 839-846.	1.2	78
31	Comparison of Tightly Controlled Dose Reduction of Biologics With Usual Care for Patients With Psoriasis. JAMA Dermatology, 2020, 156, 393.	4.1	29
32	Disease and Treatment Characteristics in Geriatric Psoriasis: A Patient Survey Comparing Age Groups. Acta Dermato-Venereologica, 2020, 100, adv00215.	1.3	11
33	Health Economic Consequences of a Tightly Controlled Dose Reduction Strategy for Adalimumab, Etanercept and Ustekinumab Compared with Standard Psoriasis Care: A Cost-utility Analysis of the CONDOR Study. Acta Dermato-Venereologica, 2020, 100, adv00340.	1.3	13
34	The effect of adalimumab on the vasculature in psoriatic skin lesions. Journal of Dermatological Treatment, 2019, 30, 221-226.	2.2	12
35	A cross-sectional study in young adults with psoriasis: potential determining factors in quality of life, life course and work productivity. Journal of Dermatological Treatment, 2019, 30, 208-215.	2.2	22
36	Psoriasis dermatitis: an overlap condition of psoriasis and atopic dermatitis in children. Journal of the European Academy of Dermatology and Venereology, 2019, 33, e74-e76.	2.4	15

#	ARTICLE	IF	CITATIONS
37	Development of a Novel Approach to Studying Corneodesmosomes and Stratum Corneum Adhesion: Extending Knowledge on the Pathophysiology of Sensitive Skin. <i>Skin Pharmacology and Physiology</i> , 2019, 32, 81-93.	2.5	2
38	Feasibility and Utility of the Psoriasis Symptom Inventory (PSI) in Clinical Care Settings: A Study from the International Psoriasis Council. <i>American Journal of Clinical Dermatology</i> , 2019, 20, 699-709.	6.7	5
39	The association of scalp psoriasis with overall psoriasis severity and koebnerization in children: cross-sectional findings from the Dutch ChildCAPTURE registry. <i>British Journal of Dermatology</i> , 2019, 181, 1099-1101.	1.5	4
40	Augmentation of Understanding in Clinical Practice and Big Data Analytics. <i>Dermatology</i> , 2019, 235, 253-254.	2.1	0
41	Switching from a fumaric acid ester mixture to dimethylfumarate monotherapy in psoriasis. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2019, 33, e352-e353.	2.4	3
42	Economic evaluation of a tailored therapist-guided internet-based cognitive behavioural treatment for patients with psoriasis: a randomized controlled trial. <i>British Journal of Dermatology</i> , 2019, 181, 614-616.	1.5	3
43	The dynamics of endothelial changes in vivo following standardized skin injury. <i>Skin Research and Technology</i> , 2019, 25, 618-624.	1.6	1
44	Severity, heterogeneity and systemic inflammation in psoriasis. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2019, 33, 643-647.	2.4	43
45	Biosimilars for Psoriasis: Experience from Europe. <i>Current Dermatology Reports</i> , 2019, 8, 26-34.	2.1	6
46	Benefit-risk profile of tofacitinib in patients with moderate-to-severe chronic plaque psoriasis: pooled analysis across six clinical trials. <i>British Journal of Dermatology</i> , 2019, 180, 67-75.	1.5	33
47	Effects of red light on inflammation and skin barrier recovery following acute perturbation. Pilot study results in healthy human subjects. <i>Photodermatology Photoimmunology and Photomedicine</i> , 2019, 35, 275-276.	1.5	0
48	Ixekizumab provides superior efficacy compared with ustekinumab over 52 weeks of treatment: Results from IXORA-S, a phase 3 study. <i>Journal of the American Academy of Dermatology</i> , 2019, 80, 70-79.e3.	1.2	77
49	Secukinumab treatment in new-onset psoriasis: aiming to understand the potential for disease modification – rationale and design of the randomized, multicenter STEPI study. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2018, 32, 1930-1939.	2.4	40
50	The efficacy and safety of non-pharmacological therapies for the treatment of acne vulgaris: A systematic review and best-evidence synthesis. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2018, 32, 1195-1203.	2.4	31
51	Prevalence of genital psoriasis in patients with psoriasis. <i>Journal of Dermatological Treatment</i> , 2018, 29, 754-760.	2.2	36
52	The load tolerance of skin during impact on artificial turf using ex-vivo skin as the readout system. <i>Science and Medicine in Football</i> , 2018, 2, 39-46.	2.0	0
53	Effects of blue light on inflammation and skin barrier recovery following acute perturbation. Pilot study results in healthy human subjects. <i>Photodermatology Photoimmunology and Photomedicine</i> , 2018, 34, 184-193.	1.5	20
54	The journey of adult psoriasis patients towards biologics: past and present – Results from the BioCAPTURE registry. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2018, 32, 615-623.	2.4	24

#	ARTICLE	IF	CITATIONS
55	Improvements in psoriasis within different body regions vary over time following treatment with ixekizumab. <i>Journal of Dermatological Treatment</i> , 2018, 29, 220-229.	2.2	14
56	Clinical use of dimethyl fumarate in moderate-to-severe plaque-type psoriasis: a European expert consensus. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2018, 32, 3-14.	2.4	76
57	The Dermatologist and psoriatic arthritis. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2018, 32, 1836-1837.	2.4	0
58	The value of (video)dermoscopy in the diagnosis and monitoring of common inflammatory skin diseases: a systematic review. <i>European Journal of Dermatology</i> , 2018, 28, 575-596.	0.6	9
59	Treatment failure in superficial basal cell carcinoma following treatment with photodynamic therapy: is this a result of underdiagnosis?. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2017, 31, e50-e52.	2.4	3
60	Psoriasis and Atopic Dermatitis. <i>Dermatology and Therapy</i> , 2017, 7, 31-41.	3.0	60
61	A European subset analysis from the population-based Multinational Assessment of Psoriasis and Psoriatic Arthritis shows country-specific features: results from psoriasis patients in Spain. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2017, 31, 1176-1182.	2.4	10
62	Sensitive skin and the influence of female hormone fluctuations: results from a cross-sectional digital survey in the Dutch population. <i>European Journal of Dermatology</i> , 2017, 27, 42-48.	0.6	18
63	Treatment Adherence Intervention Studies in Dermatology and Guidance on How to Support Adherence. <i>American Journal of Clinical Dermatology</i> , 2017, 18, 253-271.	6.7	49
64	Subclinical enthesitis in nail psoriasis patients: a case-control study. <i>JDDG - Journal of the German Society of Dermatology</i> , 2017, 15, 405-412.	0.8	8
65	Subklinische Enthesitis bei Nagelpsoriasis-Patienten: eine Fall-Kontroll-Studie. <i>JDDG - Journal of the German Society of Dermatology</i> , 2017, 15, 405-413.	0.8	3
66	Ixekizumab treatment improves fingernail psoriasis in patients with moderate-to-severe psoriasis: results from the randomized, controlled and open-label phases of UNCOVER-3. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2017, 31, 477-482.	2.4	71
67	Risk factors associated with sensitive skin and potential role of lifestyle habits: a cross-sectional study. <i>Clinical and Experimental Dermatology</i> , 2017, 42, 656-658.	1.3	13
68	Impact of ixekizumab treatment on skin-related personal relationship difficulties in moderate-to-severe psoriasis patients: 12-week results from two Phase 3 trials. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2017, 31, 1867-1875.	2.4	12
69	Guideline-based clinical decision support in acne patients receiving isotretinoin: improving adherence and cost-effectiveness. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2017, 31, e440-e442.	2.4	1
70	Response of the Endothelium to the Epicutaneous Application of Leukotriene B ₄ . <i>Skin Pharmacology and Physiology</i> , 2017, 30, 306-314.	2.5	5
71	Use of oral antidepressants in patients with chronic pruritus: A systematic review. <i>Journal of the American Academy of Dermatology</i> , 2017, 77, 1068-1073.e7.	1.2	60
72	Cognitive Schemas in Placebo and Nocebo Responding: Role of Autobiographical Memories and Expectations. <i>Clinical Therapeutics</i> , 2017, 39, 502-512.e1.	2.5	14

#	ARTICLE	IF	CITATIONS
73	Tight controlled dose reduction of biologics in psoriasis patients with low disease activity: a randomized pragmatic non-inferiority trial. <i>BMC Dermatology</i> , 2017, 17, 6.	2.1	15
74	Efficacy and safety of LAS41008 (dimethyl fumarate) in adults with moderate-to-severe chronic plaque psoriasis: a randomized, double-blind, Fumaderm [®] - and placebo-controlled trial (BRIDGE). <i>British Journal of Dermatology</i> , 2017, 176, 615-623.	1.5	111
75	Polymorphisms in <i>CD84</i> , <i>IL12B</i> and <i>TNFAIP3</i> are associated with response to biologics in patients with psoriasis. <i>British Journal of Dermatology</i> , 2017, 176, 1288-1296.	1.5	42
76	Comparison of the 1- and 5-year effectiveness of adalimumab, etanercept and ustekinumab in patients with psoriasis in daily clinical practice: results from the prospective BioCAPTURE registry. <i>British Journal of Dermatology</i> , 2017, 176, 1001-1009.	1.5	45
77	Validation of the Simplified Psoriasis Index in Dutch children and adolescents with plaque psoriasis. <i>British Journal of Dermatology</i> , 2017, 176, 771-776.	1.5	10
78	The Epidemiology and Clinicopathological Features of Basal Cell Carcinoma in Patients 80 Years and Older. <i>JAMA Dermatology</i> , 2017, 153, 71.	4.1	38
79	Predictors of perceived stigmatization in patients with psoriasis. <i>British Journal of Dermatology</i> , 2017, 176, 687-694.	1.5	63
80	Frequency and predictors of a high clinical response in patients with psoriasis on biological therapy in daily practice: results from the prospective, multicenter BioCAPTURE cohort. <i>British Journal of Dermatology</i> , 2017, 176, 786-793.	1.5	37
81	Measurement of skin surface biomarkers by Transdermal Analyses Patch following different <i>in vivo</i> models of irritation: a pilot study. <i>Skin Research and Technology</i> , 2017, 23, 336-345.	1.6	14
82	Minimizing nocebo effects by conditioning with verbal suggestion: A randomized clinical trial in healthy humans. <i>PLoS ONE</i> , 2017, 12, e0182959.	2.5	56
83	Body mass index predicts discontinuation due to ineffectiveness and female sex predicts discontinuation due to side-effects in patients with psoriasis treated with adalimumab, etanercept or ustekinumab in daily practice: a prospective, comparative, long-t. <i>British Journal of Dermatology</i> , 2016, 175, 340-347.	1.5	65
84	A four-phase strategy for the implementation of reflectance confocal microscopy in dermatology. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2016, 30, 1308-1314.	2.4	7
85	Tailored Therapist-Guided Internet-Based Cognitive Behavioral Treatment for Psoriasis: A Randomized Controlled Trial. <i>Psychotherapy and Psychosomatics</i> , 2016, 85, 297-307.	8.8	44
86	Comment on "Review of patient registries in dermatology". <i>Journal of the American Academy of Dermatology</i> , 2016, 75, e241.	1.2	1
87	Secukinumab long-term safety experience: A pooled analysis of 10 phase II and III clinical studies in patients with moderate to severe plaque psoriasis. <i>Journal of the American Academy of Dermatology</i> , 2016, 75, 83-98.e4.	1.2	264
88	Improving the applicability of guidelines on nonmelanoma skin cancer in frail older adults: a multidisciplinary expert consensus and systematic review of current guidelines. <i>British Journal of Dermatology</i> , 2016, 175, 1003-1010.	1.5	19
89	Comparison of the Dermatology Life Quality Index and the Children's Dermatology Life Quality Index in assessment of quality of life in patients with psoriasis aged 16-17 years. <i>British Journal of Dermatology</i> , 2016, 174, 152-157.	1.5	36
90	Placebo and nocebo effects on itch: effects, mechanisms, and predictors. <i>European Journal of Pain</i> , 2016, 20, 8-13.	2.8	42

#	ARTICLE	IF	CITATIONS
91	Values and costs in the management of psoriasis. Journal of Dermatological Treatment, 2016, 27, 393-394.	2.2	0
92	An outpatient multidisciplinary training programme for children and adolescents with psoriasis and their parents: a pilot study. European Journal of Dermatology, 2016, 26, 393-395.	0.6	7
93	Skin cancer care in institutionalized elderly in the Netherlands: a nationwide study on the role of nursing home physicians. Journal of the European Academy of Dermatology and Venereology, 2016, 30, e236-e237.	2.4	7
94	Fumaric acid esters in recalcitrant pediatric psoriasis: A prospective, daily clinical practice case series. Journal of Dermatological Treatment, 2016, 27, 214-220.	2.2	19
95	Implicit stigmatization-related biases in individuals with skin conditions and their significant others.. Health Psychology, 2016, 35, 861-865.	1.6	26
96	Physician perspectives in the management of psoriasis and psoriatic arthritis: results from the population-based Multinational Assessment of Psoriasis and Psoriatic Arthritis survey. Journal of the European Academy of Dermatology and Venereology, 2015, 29, 2002-2010.	2.4	139
97	Treatment of paediatric scalp psoriasis with calcipotriene/betamethasone dipropionate scalp formulation: effectiveness, safety and influence on children's quality of life in daily practice. Journal of the European Academy of Dermatology and Venereology, 2015, 29, 1193-1197.	2.4	26
98	Prioritizing dermatoses: rationally selecting guideline topics. Journal of the European Academy of Dermatology and Venereology, 2015, 29, 1636-1640.	2.4	4
99	Clearing of psoriasis documented by laser Doppler perfusion imaging contrasts remaining elevation of dermal expression levels of CD31. Skin Research and Technology, 2015, 21, 340-345.	1.6	13
100	Tofacitinib versus etanercept or placebo in moderate-to-severe chronic plaque psoriasis: a phase 3 randomised non-inferiority trial. Lancet, The, 2015, 386, 552-561.	13.7	350
101	The value of <i>in vivo</i> reflectance confocal microscopy in the diagnosis and monitoring of inflammatory and infectious skin diseases: a systematic review. British Journal of Dermatology, 2015, 172, 1222-1248.	1.5	48
102	Predictors of adalimumab drug survival in psoriasis differ by reason for discontinuation: long-term results from the BioCAPTURE registry. Journal of the European Academy of Dermatology and Venereology, 2015, 29, 560-565.	2.4	37
103	Systemic treatments in paediatric psoriasis: a systematic evidence-based update. Journal of the European Academy of Dermatology and Venereology, 2015, 29, 425-437.	2.4	41
104	Placebo Effects on Itch: A Meta-Analysis of Clinical Trials of Patients with Dermatological Conditions. Journal of Investigative Dermatology, 2015, 135, 1234-1243.	0.7	83
105	Disease recurrence in localized scleroderma: a retrospective analysis of 344 patients with paediatric- or adult-onset disease. British Journal of Dermatology, 2015, 172, 722-728.	1.5	60
106	Current Dermatologic Care in Dutch Nursing Homes and Possible Improvements: A Nationwide Survey. Journal of the American Medical Directors Association, 2015, 16, 714.e1-714.e6.	2.5	11
107	Psoriasis in Children and Adolescents: Diagnosis, Management and Comorbidities. Paediatric Drugs, 2015, 17, 373-384.	3.1	160
108	“Patient-centered treatment” for mild-to-moderate psoriasis. Journal of Dermatological Treatment, 2015, 26, 1-6.	2.2	7

#	ARTICLE	IF	CITATIONS
109	Drug Survival Studies in Dermatology: Principles, Purposes, and Pitfalls. Journal of Investigative Dermatology, 2015, 135, 1-5.	0.7	79
110	Noninvasive differentiation between stable and unstable chronic plaque psoriasis using inÂvivo reflectance confocal microscopy. Journal of the American Academy of Dermatology, 2015, 73, 870-872.	1.2	8
111	A national study on adherence to a basal cell carcinoma guideline; development of a tool to assess guideline adherence. British Journal of Dermatology, 2015, 172, 1008-1013.	1.5	8
112	How to personalize the treatment of psoriasis with biologics?. Journal of Dermatological Treatment, 2015, 26, 101-102.	2.2	0
113	Dermatological exposure to coal tar and bladder cancer risk: A case-control study. Urologic Oncology: Seminars and Original Investigations, 2015, 33, 20.e19-20.e22.	1.6	16
114	An increased risk of nonâ€melanoma skin cancer during <scp>TNF</scp>â€inhibitor treatment in psoriasis patients compared to rheumatoid arthritis patients probably relates to diseaseâ€related factors. Journal of the European Academy of Dermatology and Venereology, 2015, 29, 752-760.	2.4	51
115	An Update on Topical Therapies for Mild-Moderate Psoriasis. Dermatologic Clinics, 2015, 33, 73-77.	1.7	33
116	Dermatology: Where are We Coming from and Where are We Going to?. Frontiers in Medicine, 2014, 1, 40.	2.6	0
117	â€Happyâ€™ drug survival of adalimumab, etanercept and ustekinumab in psoriasis in daily practice care: results from the Bio<scp>CAPTURE</scp> network. British Journal of Dermatology, 2014, 171, 1189-1196.	1.5	89
118	Unmet needs in the treatment of psoriasis. European Journal of Dermatology, 2014, 24, 523-532.	0.6	24
119	Whole field laser Doppler imaging of the microcirculation in psoriasis and clinically unaffected skin. Journal of Dermatological Treatment, 2014, 25, 18-21.	2.2	22
120	Role of Conditioning and Verbal Suggestion in Placebo and Nocebo Effects on Itch. PLoS ONE, 2014, 9, e91727.	2.5	105
121	Understanding the Acute Skin Injury Mechanism Caused by Player-Surface Contact During Soccer. Orthopaedic Journal of Sports Medicine, 2014, 2, 232596711453348.	1.7	18
122	Establishing the dynamics of neutrophil accumulation <i>in vivo</i> by reflectance confocal microscopy. Experimental Dermatology, 2014, 23, 184-188.	2.9	21
123	Increased prevalence of psoriasis in patients with coronary artery disease. British Journal of Dermatology, 2014, 171, 450-450.	1.5	1
124	The psychophysiological stress response in psoriasis and rheumatoid arthritis. British Journal of Dermatology, 2014, 170, 824-831.	1.5	26
125	Satisfaction of treatment with biologics is high in psoriasis: results from the Bio-CAPTURE network. British Journal of Dermatology, 2014, 170, 1158-1165.	1.5	28
126	The effect of adalimumab on key drivers in the pathogenesis of psoriasis. British Journal of Dermatology, 2014, 170, 571-580.	1.5	20

#	ARTICLE	IF	CITATIONS
127	The effectiveness and safety of short-contact dithranol therapy in paediatric psoriasis: a prospective comparison of regular day care and day care with telemedicine. <i>British Journal of Dermatology</i> , 2014, 170, 454-457.	1.5	39
128	Comparing treatment goals for psoriasis with treatment decisions in daily practice: results from a prospective cohort of patients with psoriasis treated with biologics: Bio CAPTURE. <i>British Journal of Dermatology</i> , 2014, 171, 1091-1098.	1.5	20
129	Increased incidence of squamous cell carcinoma of the skin after long-term treatment with azathioprine in patients with autoimmune inflammatory rheumatic diseases. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2014, 28, 27-33.	2.4	34
130	Determinants of drug survival for etanercept in a long-term daily practice cohort of patients with psoriasis. <i>British Journal of Dermatology</i> , 2014, 170, 415-424.	1.5	39
131	Are Newly Discovered Drivers of Immune-Mediated Skin Disorders Expressed in Normal Skin Regenerating from Standardized Surface Injury?. <i>Dermatology</i> , 2014, 228, 255-260.	2.1	11
132	The prevalence of onychomycosis in psoriatic patients: a systematic review. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2014, 28, 533-541.	2.4	71
133	Cutaneous Application of Leukotriene B ₄ as an in vivo Model of Psoriasis-Like Skin Inflammation: An Immunohistological Study. <i>Skin Pharmacology and Physiology</i> , 2014, 27, 120-126.	2.5	15
134	Scoring nail psoriasis. <i>Journal of the American Academy of Dermatology</i> , 2014, 70, 1061-1066.	1.2	46
135	In Vivo Induction of Cutaneous Inflammation Results in the Accumulation of Extracellular Trap-Forming Neutrophils Expressing ROR γ t and IL-17. <i>Journal of Investigative Dermatology</i> , 2014, 134, 1276-1284.	0.7	107
136	Immune responses to stress in rheumatoid arthritis and psoriasis. <i>Rheumatology</i> , 2014, 53, 1844-1848.	1.9	20
137	Calcipotriol/betamethasone dipropionate ointment in mild-to-moderate paediatric psoriasis: long-term daily clinical practice data in a prospective cohort. <i>British Journal of Dermatology</i> , 2014, 171, 363-369.	1.5	33
138	New developments in our understanding of psoriatic arthritis and their impact on the diagnosis and clinical management of the disease. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2014, 28, 264-270.	2.4	20
139	Patient perspectives in the management of psoriasis: Results from the population-based Multinational Assessment of Psoriasis and Psoriatic Arthritis Survey. <i>Journal of the American Academy of Dermatology</i> , 2014, 70, 871-881.e30.	1.2	423
140	Nail Psoriasis, the unknown burden of disease. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2014, 28, 1690-1695.	2.4	58
141	Adalimumab therapy for psoriasis in real-world practice: efficacy, safety and results in biologic-naïve vs. non-naïve patients. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2013, 27, 593-600.	2.4	32
142	Combinations of classical time-honoured topicals in plaque psoriasis: a systematic review. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2013, 27, 399-410.	2.4	19
143	Efficacy and safety of combinations of first-line topical treatments in chronic plaque psoriasis: a systematic literature review. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2013, 27, 931-951.	2.4	32
144	Long-term management of scalp psoriasis: perspectives from the international psoriasis council. <i>Journal of Dermatological Treatment</i> , 2013, 24, 188-192.	2.2	19

#	ARTICLE	IF	CITATIONS
145	Nail psoriasis: a questionnaire-based survey. British Journal of Dermatology, 2013, 169, 314-319.	1.5	74
146	Balance of Treg vs. T-helper cells in the transition from symptomless to lesional psoriatic skin. British Journal of Dermatology, 2013, 168, 1294-1302.	1.5	40
147	Innovations in the treatment of psoriasis and non-melanoma skin cancers. Journal of Dermatological Treatment, 2013, 24, 161-161.	2.2	0
148	THU0590â€¦The Patient-Therapist Relationship as An Indicator for Treatment Success in E-Health Treatments for Patients with Rheumatoid Arthritis and Psoriasis. Annals of the Rheumatic Diseases, 2013, 72, A364.2-A364.	0.9	0
149	Apremilast: a step forward in the treatment of psoriasis?. Lancet, The, 2012, 380, 708-709.	13.7	2
150	Paediatric-onset psoriasis is associated with<i>ERAP1</i>and<i>IL23R</i>loci,<i>LCE3C_LCE3B</i>deletion and<i>HLA-C*06</i>. British Journal of Dermatology, 2012, 167, 922-925.	1.5	31
151	Efficacy of blue light vs. red light in the treatment of psoriasis: a double-blind, randomized comparative study. Journal of the European Academy of Dermatology and Venereology, 2012, 26, 219-225.	2.4	47
152	Safety of treatment with biologics for psoriasis in daily practice: 5â€¢year data. Journal of the European Academy of Dermatology and Venereology, 2012, 26, 283-291.	2.4	34
153	Role of induced negative and positive emotions in sensitivity to itch and pain in women. British Journal of Dermatology, 2012, 167, 262-269.	1.5	42
154	Reflectance confocal microscopy: an effective tool for monitoring ultraviolet B phototherapy in psoriasis. British Journal of Dermatology, 2012, 167, 396-403.	1.5	32
155	The influence of treatments in daily clinical practice on the Childrenâ€™s Dermatology Life Quality Index in juvenile psoriasis: a longitudinal study from the Child-CAPTURE patient registry. British Journal of Dermatology, 2012, 167, 145-149.	1.5	51
156	A framework for improving the quality of care for people with psoriasis. Journal of the European Academy of Dermatology and Venereology, 2012, 26, 1-16.	2.4	42
157	Is â€¢class effectâ€¢™ relevant when assessing the benefit/risk profile of a biologic agent?. Journal of the European Academy of Dermatology and Venereology, 2012, 26, 9-16.	2.4	9
158	Improving clinical trial design in psoriasis: Perspectives from the global dermatology community. Journal of Dermatological Treatment, 2011, 22, 187-193.	2.2	4
159	F175 ROLE OF NEGATIVE AND POSITIVE EMOTIONS IN SENSITIVITY TO PAIN AND ITCH. European Journal of Pain Supplements, 2011, 5, 124-124.	0.0	0
160	The International Psoriasis Council Presents Top Five Psoriasis Research Articles for July 2010â€¢December 2010. Psoriasis Forum, 2011, 17a, 275-279.	0.1	0
161	Long-term, continuous dosing of etanercept in patients with plaque psoriasis. Expert Review of Dermatology, 2011, 6, 361-373.	0.3	1
162	Juvenile psoriasis in European and Asian children: similarities and differences. British Journal of Dermatology, 2011, 164, 1101-1103.	1.5	43

#	ARTICLE	IF	CITATIONS
163	Management of palmoplantar pustulosis: do we need to change?. British Journal of Dermatology, 2011, 164, 942-946.	1.5	68
164	Factors impacting the combination of topical corticosteroid therapies for psoriasis: perspectives from the international psoriasis council. Journal of the European Academy of Dermatology and Venereology, 2011, 25, 1130-1139.	2.4	31
165	I use sunscreens but is it really safe under the sun?. Journal of Dermatological Treatment, 2011, 22, 61-61.	2.2	0
166	Acitretin revisited in the era of biologics. Journal of Dermatological Treatment, 2011, 22, 86-89.	2.2	37
167	Pustulosis palmoplantaris is a disease distinct from psoriasis. Journal of Dermatological Treatment, 2011, 22, 102-105.	2.2	70
168	No evidence found that childhood onset of psoriasis influences disease severity, future body mass index or type of treatments used. Journal of the European Academy of Dermatology and Venereology, 2010, 24, 1333-1339.	2.4	33
169	Novel biologic therapies in development targeting IL-12/IL-23. Journal of the European Academy of Dermatology and Venereology, 2010, 24, 5-9.	2.4	8
170	Switching from etanercept to adalimumab is effective and safe: results in 30 patients with psoriasis with primary failure, secondary failure or intolerance to etanercept. British Journal of Dermatology, 2010, 163, 838-846.	1.5	45
171	A cross-sectional study using the Children's Dermatology Life Quality Index (CDLQI) in childhood psoriasis: negative effect on quality of life and moderate correlation of CDLQI with severity scores. British Journal of Dermatology, 2010, 163, 1099-1101.	1.5	72
172	The values of treatments for chronic inflammatory skin diseases; challenges of the market of health. Journal of Dermatological Treatment, 2010, 21, 1-2.	2.2	3
173	Topical treatments in dermatology still going strong. Journal of Dermatological Treatment, 2010, 21, 125-125.	2.2	0
174	Expression of p14 ARF, p16 INK4a and p53 in relation to HPV in (pre-)malignant squamous skin tumours. Journal of Cellular and Molecular Medicine, 2009, 13, 2148-2157.	3.6	11
175	Induction of protoporphyrin IX by aminolaevulinic acid in actinic keratosis, psoriasis and normal skin: preferential porphyrin enrichment in differentiated cells. British Journal of Dermatology, 2009, 160, 849-857.	1.5	23
176	Three-year registry data on biological treatment for psoriasis: the influence of patient characteristics on treatment outcome. British Journal of Dermatology, 2009, 160, 670-675.	1.5	72
177	Individual differences in the effect of daily stressors on psoriasis: a prospective study. British Journal of Dermatology, 2009, 161, 295-299.	1.5	76
178	Textbook of Atopic Dermatitis. Journal of Dermatological Treatment, 2009, 20, 70-70.	2.2	0
179	A comparison of twice-daily calcipotriol ointment with once-daily short-contact dithranol cream therapy: quality-of-life outcomes of a randomized controlled trial of supervised treatment of psoriasis in a day-care setting. British Journal of Dermatology, 2008, 158, 375-381.	1.5	29
180	Psoriasis: consensus on topical therapies. Journal of the European Academy of Dermatology and Venereology, 2008, 22, 859-870.	2.4	29

#	ARTICLE	IF	CITATIONS
181	Period of remission after treatment with UVAâ€ in sclerodermic skin diseases. Journal of the European Academy of Dermatology and Venereology, 2008, 22, 839-844.	2.4	24
182	Analysis of 3-year national reimbursement application data on etanercept and efalizumab for psoriasis. British Journal of Dermatology, 2008, 159, 760-761.	1.5	4
183	Once weekly administration of etanercept 50â€mg is efficacious and well tolerated in patients with moderate-to-severe plaque psoriasis: a randomized controlled trial with open-label extension. British Journal of Dermatology, 2008, 159, ???-???.	1.5	149
184	Options for the treatment of psoriasis: a multifactorial approach. Clinics in Dermatology, 2008, 26, 419-423.	1.6	7
185	Psoriasis of the face and flexures. Journal of Dermatological Treatment, 2007, 18, 351-360.	2.2	33
186	A double-blind, randomized quantitative comparison of calcitriol ointment and calcipotriol ointment on epidermal cell populations, proliferation and differentiation. British Journal of Dermatology, 2007, 156, 130-137.	1.5	16
187	Oral retinoic acid metabolism blocking agent RambazoleTM for plaque psoriasis: an immunohistochemical study. British Journal of Dermatology, 2007, 156, 263-270.	1.5	31
188	The evolution of the psoriatic lesion. British Journal of Dermatology, 2007, 157, 4-15.	1.5	39
189	The Impact of Chronic Skin Disease on Daily Life (ISDL): a generic and dermatology-specific health instrument. British Journal of Dermatology, 2007, 158, 071115063928006-???.	1.5	89
190	Sedentary patients with venous or mixed leg ulcers: determinants of physical activity. Journal of Advanced Nursing, 2007, 60, 50-57.	3.3	27
191	Oral R115866 in the treatment of moderate to severe plaqueâ€type psoriasis. Journal of the European Academy of Dermatology and Venereology, 2007, 21, 1038-1046.	2.4	34
192	Effect of calcipotriol on epidermal cell populations in alefacept-treated psoriatic lesions. Journal of the European Academy of Dermatology and Venereology, 2006, 20, 27-33.	2.4	9
193	Consistent control of psoriasis by continuous long-term therapy: the promise of biological treatments. Journal of the European Academy of Dermatology and Venereology, 2006, 20, 639-650.	2.4	35
194	The unmet treatment need for moderate to severe psoriasis: results of a survey and chart review. Journal of the European Academy of Dermatology and Venereology, 2006, 20, 060628090810004-???.	2.4	29
195	Therapeutic effects of a 12-week course of alefacept on nail psoriasis. Journal of the European Academy of Dermatology and Venereology, 2006, 20, 1252-1255.	2.4	36
196	Update on retinoid therapy of psoriasis in: an update on the use of retinoids in dermatology. Dermatologic Therapy, 2006, 19, 252-263.	1.7	84
197	Efficacy of the pulsed dye laser in the treatment of localized recalcitrant plaque psoriasis: a comparative study. British Journal of Dermatology, 2006, 155, 110-114.	1.5	31
198	Induction of eruptive benign melanocytic naevi by immune suppressive agents, including biologicals. British Journal of Dermatology, 2006, 154, 880-884.	1.5	89

#	ARTICLE	IF	CITATIONS
199	A placebo-controlled randomized study on the clinical effectiveness, immunohistochemical changes and protoporphyrin IX accumulation in fractionated 5-aminolaevulinic acid-photodynamic therapy in patients with psoriasis. <i>British Journal of Dermatology</i> , 2006, 155, 429-436.	1.5	48
200	Heterogeneity of fluorescence in psoriasis after application of 5-aminolaevulinic acid: an immunohistochemical study. <i>British Journal of Dermatology</i> , 2006, 155, 539-545.	1.5	33
201	A comparison of twice-daily calcipotriol ointment with once-daily short-contact dithranol cream therapy: a randomized controlled trial of supervised treatment of psoriasis vulgaris in a day-care setting. <i>British Journal of Dermatology</i> , 2006, 155, 800-807.	1.5	35
202	Assessment of epidermal subpopulations and proliferation in healthy skin, symptomless and lesional skin of spreading psoriasis. <i>British Journal of Dermatology</i> , 2006, 155, 688-694.	1.5	30
203	Evidence-based and patient-based dermatology. <i>Journal of Dermatological Treatment</i> , 2006, 17, 197-197.	2.2	0
204	Current and future treatment options for acne. <i>Journal of Dermatological Treatment</i> , 2006, 17, 198-204.	2.2	16
205	Quality of life in vitiligo patients after treatment with long-term narrowband ultraviolet B phototherapy. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2005, 19, 56-60.	2.4	20
206	Recommendations for the topical treatment of psoriasis. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2005, 19, 495-499.	2.4	12
207	Follicular cysts and hyperkeratoses as first manifestation, and involvement of the central nervous system as late manifestation of mycosis fungoides. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2005, 19, 777-779.	2.4	10
208	Plaque psoriasis vs. atopic dermatitis and lichen planus: a comparison for lesional T-cell subsets, epidermal proliferation and differentiation. <i>British Journal of Dermatology</i> , 2005, 153, 72-78.	1.5	99
209	Common burden of chronic skin diseases? Contributors to psychological distress in adults with psoriasis and atopic dermatitis. <i>British Journal of Dermatology</i> , 2005, 152, 1275-1281.	1.5	176
210	The topical treatment of psoriasis. <i>Clinical and Experimental Dermatology</i> , 2005, 30, 205-208.	1.3	11
211	Alefacept in the Treatment of Psoriasis in Patients for Whom Conventional Therapies Are Inadequate. <i>Dermatology</i> , 2005, 211, 256-263.	2.1	18
212	A Two-Compound Product Containing Calcipotriol and Betamethasone Dipropionate Provides Rapid, Effective Treatment of Psoriasis vulgaris regardless of Baseline Disease Severity. <i>Dermatology</i> , 2005, 210, 294-299.	2.1	28
213	The impact of a two-compound product containing calcipotriol and betamethasone dipropionate (DaivobetR/ DovobetR) on the quality of life in patients with psoriasis vulgaris: a randomized controlled trial. <i>British Journal of Dermatology</i> , 2004, 151, 663-668.	1.5	50
214	Established Treatments of Psoriasis. <i>Inflammation and Allergy: Drug Targets</i> , 2004, 3, 145-156.	3.1	17
215	Age-based treatment differences in and reluctance to treating older adults with systemic antipsoriatic therapy – a mixed-method pilot study. <i>Journal of Dermatological Treatment</i> , 0, , 1-9.	2.2	0